Maraviroc (Selzentry) | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Historical source

Original GlobalRPh source

Product / population: Preserved GlobalRPh source, not a freshly verified product label
Renal measure: Use the method specified in the original source

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

Indication and tropism comments

SELZENTRY is used in combination for adult HIV-1 infection with only CCR5-tropic virus. The source describes two studies in treatment-experienced adults with three-class experience (NRTI, NNRTI, protease inhibitor and/or enfuvirtide) and ongoing replication, and one study in treatment-naive adults.

A highly sensitive validated tropism test is required. Outgrowth of previously undetected low-level CXCR4-tropic or dual/mixed virus can cause failure. The source reports no efficacy in a phase 2 study of dual/mixed or CXCR4 virus. It also describes unestablished pediatric use in that historical labeling and more virologic failure/lamivudine resistance in treatment-naive recipients than with efavirenz.

Usual Dosing (Adults)

Always combine with other antiretrovirals; take with or without food. Dose depends on coadministered drugs:

Potent CYP3A inhibitors, with or without an inducer: 150 mg twice daily. Examples include protease inhibitors except tipranavir/ritonavir, delavirdine, ketoconazole, itraconazole, clarithromycin, nefazodone and telithromycin.
Other drugs: 300 mg twice daily. Examples include tipranavir/ritonavir, nevirapine, raltegravir, NRTIs and enfuvirtide.
Potent CYP3A inducers without a potent inhibitor: 600 mg twice daily. Examples include efavirenz, rifampin, etravirine, carbamazepine, phenobarbital and phenytoin.

Renal Dosing and hemodialysis

For normal (CrCl above 80), mild (above 50 to 80) or moderate (30-50 mL/min) impairment: use the interaction-specific regimens above.

For severe impairment (CrCl below 30) and ESRD receiving hemodialysis:

With potent CYP3A inhibitors, with or without inducers: not recommended in the source table.
With drugs in the 'other' group: 300 mg twice daily; reduce to 150 mg twice daily if postural hypotension occurs.
With potent CYP3A inducers without an inhibitor: not recommended.

The separate hemodialysis heading supplies no additional instruction beyond this table.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/maraviroc-selzentry/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Preserved GlobalRPh source

Original GlobalRPh protocol and comments

Preserved source. Not revalidated as current labeling.

Method: Use the measure stated in the original section.

Usual Dosing (Adults)Renal Dosing and hemodialysis Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope

Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Compare original content

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/maraviroc-selzentry/

Indication and tropism comments

GRPH-maraviroc-selzentry-01 · Source section: Indication and tropism commentsRenal section finder

Usual Dosing (Adults)

Always combine with other antiretrovirals; take with or without food. Dose depends on coadministered drugs:

Potent CYP3A inhibitors, with or without an inducer: 150 mg twice daily. Examples include protease inhibitors except tipranavir/ritonavir, delavirdine, ketoconazole, itraconazole, clarithromycin, nefazodone and telithromycin.
Other drugs: 300 mg twice daily. Examples include tipranavir/ritonavir, nevirapine, raltegravir, NRTIs and enfuvirtide.
Potent CYP3A inducers without a potent inhibitor: 600 mg twice daily. Examples include efavirenz, rifampin, etravirine, carbamazepine, phenobarbital and phenytoin.

GRPH-maraviroc-selzentry-02 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing and hemodialysis

For normal (CrCl above 80), mild (above 50 to 80) or moderate (30-50 mL/min) impairment: use the interaction-specific regimens above.

For severe impairment (CrCl below 30) and ESRD receiving hemodialysis:

With potent CYP3A inhibitors, with or without inducers: not recommended in the source table.
With drugs in the 'other' group: 300 mg twice daily; reduce to 150 mg twice daily if postural hypotension occurs.
With potent CYP3A inducers without an inhibitor: not recommended.

The separate hemodialysis heading supplies no additional instruction beyond this table.

GRPH-maraviroc-selzentry-03 · Source section: Renal Dosing and hemodialysisRenal section finder

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/renal/maraviroc-selzentry/
Source retrieval: 2026-09-05. This is not the source publication or label revision date.
Original source type: globalrph individual
Local text SHA-256: dddec5fedae3a0fcd722be28136c95a605527a44990ba3bf697e2c40f226c8b1
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report